Sale!

Arthrogryposis and Congenital Myasthenic Syndrome Gene Panel Test Cost

Original price was: 9,880 د.إ.Current price is: 8,890 د.إ.

-10%

The “Arthrogryposis and Congenital Myasthenic Syndrome Gene Panel Test” is a comprehensive diagnostic tool offered by DNA Labs UAE, designed to identify genetic mutations associated with Arthrogryposis and Congenital Myasthenic Syndrome (CMS). Arthrogryposis refers to a range of conditions characterized by joint contractures and muscle weakness present at birth, while CMS encompasses a group of genetic disorders that result in muscle fatigue and weakness due to impaired transmission of signals between nerves and muscles.

This gene panel test targets specific genes known to be linked to these conditions, facilitating an accurate diagnosis and enabling healthcare providers to tailor treatment plans effectively. Given the genetic complexity and variability of these disorders, the panel approach increases the likelihood of identifying the underlying genetic cause.

Priced at 8890 AED, the test represents a significant investment in pinpointing the genetic underpinnings of these conditions, offering hope for affected individuals and their families for better management and understanding of their health challenges. Conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities, patients can expect a high level of accuracy and reliability in the test results, paving the way for improved outcomes.

Description

Arthrogryposis and Congenital Myasthenic syndrome Gene Panel Test

Components: Sterile container/ Sterile Normal Saline Container/ EDTA Vacutainer

Price: 8890.0 AED

Sample Condition: Amniotic fluid/ Chorionic villi/ Peripheral blood

Report Delivery: 4-6 weeks

Method: NGS (Next-Generation Sequencing)

Test Type: Genetics

Doctor: General Physician

Test Department:

Pre Test Information: Arthrogryposis and Congenital Myasthenic syndrome Gene Panel can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details:

Arthrogryposis and Congenital Myasthenic Syndrome (CMS) Gene Panel is a diagnostic tool used to identify genetic mutations associated with Arthrogryposis and CMS. Arthrogryposis is a condition characterized by the presence of multiple joint contractures at birth, while CMS is a group of genetic disorders that affect the neuromuscular junction, leading to muscle weakness and fatigue.

The panel includes genes that have been associated with Arthrogryposis and CMS, such as CHRNE, RAPSN, COLQ, DOK7, and others. The panel is typically performed using next-generation sequencing technology, which allows for the simultaneous analysis of multiple genes.

The results of the panel can help diagnose the underlying genetic cause of Arthrogryposis or CMS, which can aid in developing a treatment plan and providing genetic counseling to affected individuals and their families.

Test Name	Arthrogryposis and Congenital Myasthenic syndrome Gene Panel Test
Components	Sterile container/ Sterile Normal Saline Container/ EDTA Vacutainer
Price	8890.0 AED
Sample Condition	Amniotic fluid\/ Chorionic villi\/ Peripheral blood
Report Delivery	4-6 weeks
Method	NGS
Test type	Genetics
Doctor	General Physician
Test Department:
Pre Test Information	Arthrogryposis and Congenital Myasthenic syndrome Gene Panel can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details	Arthrogryposis and Congenital Myasthenic Syndrome (CMS) Gene Panel is a diagnostic tool used to identify genetic mutations associated with Arthrogryposis and CMS. Arthrogryposis is a condition characterized by the presence of multiple joint contractures at birth, while CMS is a group of genetic disorders that affect the neuromuscular junction, leading to muscle weakness and fatigue. The panel includes genes that have been associated with Arthrogryposis and CMS, such as CHRNE, RAPSN, COLQ, DOK7, and others. The panel is typically performed using next-generation sequencing technology, which allows for the simultaneous analysis of multiple genes. The results of the panel can help diagnose the underlying genetic cause of Arthrogryposis or CMS, which can aid in developing a treatment plan and providing genetic counseling to affected individuals and their families.